Research Topics
| Patricia M LoRussoSummaryAffiliation: Wayne State University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatmentPatricia Mucci LoRusso
Karmanos Cancer Institute Wayne State University, Detroit, MI 48201, USA
Oncology 84:43-56. 2013..In this review, we consider the translation of mTOR inhibitors from laboratory studies to large clinical trials, driven by a rational understanding of the role of mTOR in the processes that underlie breast cancer tumorigenesis...- Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta
Karmanos Cancer Institute, Department of Oncology, Detroit, MI, USA
J Natl Cancer Inst 104:1860-6. 2012..We analyzed patient outcome results in MTA phase I trials at multiple institutions throughout North America sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program... - Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop
Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 30:2307-13. 2012..Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of MK-0752... - Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan 48201, USA
Clin Cancer Res 18:2954-63. 2012..This study (NCI-6432; NCT00091117) was conducted to evaluate bortezomib pharmacokinetics and safety in patients with varying degrees of hepatic impairment, to inform dosing recommendations in these special populations... 
Toward evidence-based management of the dermatologic effects of EGFR inhibitorsPatricia LoRusso
Phase I Clinical Trial Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
Oncology (Williston Park) 23:186-94. 2009..These reports represent the first step toward an evidence-based approach to the prevention and management of these important effects...- Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesPatricia M LoRusso
Barbara Ann Karmanos Cancer Institute, 4100 John R 4 HWCRC, Room 4206, Detroit, MI 48201, USA
J Clin Oncol 23:5281-93. 2005.... - An overview of the optimal planning, design, and conduct of phase I studies of new therapeuticsPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 16:1710-8. 2010..A final article summarizes recommendations for the design and conduct of phase II studies... - Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancersPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 16:1924-37. 2010..To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901, a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor in advanced cancer patients... - Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort studyPatricia LoRusso
Karmanos Cancer Institute, Detroit, MI 48201, USA
Invest New Drugs 29:1395-405. 2011..This phase I, single-center, dose-finding study was designed primarily to investigate the safety and pharmacokinetics (PK) of cediranib with various anticancer regimens in patients with advanced solid tumors... - Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
Invest New Drugs 26:159-67. 2008..This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126... - Translating clinical trials into meaningful outcomesPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 16:5951-5. 2010..The challenge today is to develop new approaches to translate scientific discovery into cost-effective and meaningful improvements in cancer outcomes... - Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumorsPatricia LoRusso
Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI, 48201, USA
Invest New Drugs 26:455-62. 2008..Hypertension was the most common related grade 3 event (21%). No grade 4 or 5 treatment-related adverse events occurred... - Oxaliplatin in tumors other than colorectal cancerP M Lorusso
Wayne State University Karmanos Cancer Institute, Detroit, Michigan, USA
Oncology (Williston Park) 14:33-7. 2000..Ongoing and planned trials will evaluate the efficacy of oxaliplatin in other disease settings and combinations... - Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?Patricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 16:5956-62. 2010.... - Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerPatricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan, USA
Clin Cancer Res 17:6437-47. 2011..Data from the phase III trials and other studies of T-DM1-containing agents are eagerly awaited... - Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumorsPatricia LoRusso
Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA
Cancer Chemother Pharmacol 68:1377-85. 2011.... - Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potentialPatricia M LoRusso
Eisenberg Center for Translational Therapeutics, Karmanos Cancer Center, Detroit, MI 48201, USA
Cancer Chemother Pharmacol 71:193-202. 2013..Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI study with oral contraceptives (OCs)... - A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumorsElisabeth I Heath
Wayne State University Karmanos Cancer Institute, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
Invest New Drugs 26:59-65. 2008..The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution... 
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycinUlka N Vaishampayan
Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 16:3795-804. 2010..Toxicity was assessed weekly, and response was evaluated every two cycles...- Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B designShirish M Gadgeel
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
Clin Cancer Res 11:6233-9. 2005..The accelerated titration "2B" design may help in determining MTD with fewer patients enrolled and more being treated closer to the MTD. However, the accelerated titration design did not seem to shorten the study duration... - A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerElaina M Gartner
Karmanos Cancer Institute, Wayne State University, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
Breast Cancer Res Treat 131:933-7. 2012..Five patients developed grade 3/4 toxicities, which were primarily hepatic and pulmonary. Based on these results, we do not recommend further study of 17-AAG at this dosing schedule or in unselected breast cancer patients... - Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097Jianmei Wu
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
Clin Cancer Res 18:2066-79. 2012..This study investigated RO4929097 binding in plasma and its implications for the pharmacokinetics and pharmacodynamics of this compound... - A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitorAmin M Alousi
Karmanos Cancer Institute, Wayne State University School of Medicine, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA
Invest New Drugs 25:147-54. 2007..Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD)... - Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsElisabeth I Heath
Karmanos Cancer Institute, Detroit, MI 48201, USA
Cancer Chemother Pharmacol 68:703-12. 2011..To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin... - Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experienceElisabeth I Heath
Division of Hematology and Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
J Biopharm Stat 19:414-23. 2009..The theoretical advantages and disadvantages of both Phase I trial designs did not readily emerge in their actual application in clinical trials conducted at our institution... - Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan, USA
Clin Cancer Res 17:5774-82. 2011.... - Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignanciesPriscila H Goncalves
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
Invest New Drugs 26:347-54. 2008..Due to cardiac toxicity occurring with both the parent compound, SR233377, as well as this analog, this series of agents was abandoned from further clinical development... - Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
Clin Cancer Res 9:2040-8. 2003..They appeared to be a sensitive tool to monitor clinical changes for the five tumor types in these trials and showed that ZD1839 has the potential to improve patients' QoL... - Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
J Clin Oncol 26:3051-6. 2008..This phase I study assessed the safety, optimally tolerated regimen (OTR), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of lapatinib and docetaxel in patients with advanced solid tumors... - A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain
Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State, University, Detroit, MI, USA
Invest New Drugs 21:465-71. 2003..We conducted a phase II trial to evaluate the efficacy and toxicity of this agent in patients with advanced renal cell cancer (RCC)... - Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumorsBasil F El-Rayes
Division of Hematology/Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI 48201, USA
Invest New Drugs 23:57-62. 2005..Major toxicities of the combination include the hand-foot syndrome, stomatitis and neutropenia... - Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administrationRamesh R Boinpally
Division of Hematology-Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 110 East Warren, Detroit, MI 48201, USA
Cancer Chemother Pharmacol 55:404-7. 2005..CONCLUSION: Together with the antitumor efficacy of oral XK469 shown in preclinical models and its schedule dependency, these results indicate the promise of developing an oral dosage form of R-XK469 for clinical development... - Phase I studies of ZD1839 in patients with common solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201-2097, USA
Semin Oncol 30:21-9. 2003..Based on the phase I study results, once-daily oral doses of 250 mg and 500 mg, which are well below the maximum tolerated dose, were selected for further clinical investigation of ZD1839... - Phase II study of CI-958 in colorectal cancerA F Shields
Barbara Ann Karmanos Cancer Institute, Detroit Medical Center, Wayne State University, Michigan, USA
Cancer Chemother Pharmacol 43:162-4. 1999..We completed a phase II trial of CI-958 (NSC 635371) in patients with advanced colorectal cancer given at a dose of 700 mg/m2 every 21 days... - Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising futureElaina M Gartner
Departments of Internal Medicine and daggerPharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
Cancer J 16:83-90. 2010..The most recent data from the clinical trials of olaparib (AZD2281, KU-0059436), BSI-201, AG014699, ABT-888, and INO-1001 and descriptions of ongoing studies are also presented... - Clinical experience of MEK inhibitors in cancer therapyDing Wang
Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA
Biochim Biophys Acta 1773:1248-55. 2007..Several MEK inhibitors have been examined in early-phase clinical trials and the current state of clinical results using these therapies is presented here... - Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126Jeffrey L Evelhoch
Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
Clin Cancer Res 10:3650-7. 2004..CONCLUSIONS: The contrast enhanced-MRI measured median IAUC is a useful end point for quantifying ZD6126 antivascular effects in human tumors... - Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 17:2502-11. 2011..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed... - A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" designS M Gadgeel
Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
Invest New Drugs 21:63-74. 2003..8-8.4 mg/m2/d x 5. No significant correlation was observed between plasma levels and toxicity. No tumor responses were observed among the 14 patients evaluable for response... - Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an institute of medicine workshopPatricia M LoRusso
Authors Affiliations Karmanos Cancer Institute, Wayne State University, Detroit, Michigan Bristol Myers Squibb, Wallingford, Connecticut Merck Research Laboratories, Merck and Company, Inc, Rahway, New Jersey Institute of Medicine, Washington, District of Columbia and Novartis Pharma AG, Basel, Switzerland
Clin Cancer Res 18:6101-9. 2012..Clin Cancer Res; 18(22); 6101-9. ©2012 AACR... - Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU)Patricia M LoRusso
Karmanos Cancer Institute at Wayne State University School of Medicine, Department of Internal Medicine, Detroit, MI, USA
Invest New Drugs 20:63-71. 2002..CONCLUSION: 5FP is a tolerable oral outpatient therapy. Accelerated titration was an efficient way of conducting this phase I trial. The recommended phase 2 dose is 625 mg/m2/d orally for 5 days every 28 days... - The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathwaysZ Ding
Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Prentis Building, 110 East Warren, Detroit, MI 48201, USA
Clin Cancer Res 7:3336-42. 2001.... - Targeting the epidermal growth factor receptorB F El Rayes
Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University 48201, USA
Br J Cancer 91:418-24. 2004..Future issues in the development of EGFR inhibitors include the identification of biologic predictors of response, combination with other targeted agents, and their utilisation in earlier stage malignancies... - Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyondK A Keyes
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 6:2474-81. 2000..Pharmacology studies proved that protracted therapy causes little, if any, change in cellular drug tolerance or systemic exposure... - Vascular disrupting agentsM J Pilat
Department of Internal Medicine, Division of Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
J Cell Biochem 99:1021-39. 2006..More evidence suggests VDAs will have their greatest effect in combination with conventional chemotherapy or other modes of treatment that attack this outer rim of cells... - A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183Linda E Bröker
VU University Medical Center, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
Clin Cancer Res 13:3906-12. 2007..Additionally, the pharmacokinetics and possible antitumor activity were studied... - Non-rash skin toxicities associated with novel targeted therapiesMario E Lacouture
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 48201, USA
Clin Lung Cancer 8:S36-42. 2006..This review discusses several non-rash dermatologic toxicities observed with targeted therapeutic agents and guidelines for their diagnosis and treatment... - Therapeutic potential of novel selective-spectrum kinase inhibitors in oncologyPatricia M LoRusso
Barbara Ann Karmanos Cancer Institute Wayne State University, USA
Expert Opin Investig Drugs 17:1013-28. 2008..Since combination chemotherapy is most often required for optimal benefit, the potential benefit to combining targets in one agent is of considerable interest in drug development... - Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183Linda E Bröker
VU University Medical Center, Amsterdam, The Netherlands
Clin Cancer Res 14:4186-91. 2008..Pharmacokinetic sampling was done up to 72 hours after the first four doses and analyzed with a validated liquid chromatography/mass spectrometry assay... - Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson
Food and Drug Administration, WO Bldg 64, Rm 2014, 10903 New Hampshire Avenue, HFD 902, Silver Spring, MD 20993, USA
Cancer Chemother Pharmacol 56:351-7. 2005..The multiday half-life of XK469 hampered our ability to obtain a complete mass balance, and the possibility exists that other routes, such as biliary excretion, may also play a substantial role in XK469 disposition... - Differentiation and definition of vascular-targeted therapiesDietmar W Siemann
Department of Radiation Oncology, University of Florida, PO Box 100385, Gainesville, FL 32610, USA
Clin Cancer Res 11:416-20. 2005.... - Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancerJohn Rinehart
University of Alabama at Birmingham, Birmingham, AL 35294, USA
J Clin Oncol 22:4456-62. 2004.... - The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomesJoel M Reid
Department of Oncology and Mass Spectrometry Facility, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 10:1471-80. 2004..PZA, 9-desmethyl-PZA, and PZA N-oxide inhibited growth of A375 human melanoma cells. IC(50) values were 0.17, 0.11, and 7.0 micro M, respectively, for the three molecules... - In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesisDonna A Volpe
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
Cancer Chemother Pharmacol 54:89-94. 2004....
Research Grants
- Phase I Clinical Trials of New Anticancer AgentsPatricia LoRusso; Fiscal Year: 2007....